Overview
Lupus vulgaris of the nose, a form of cutaneous tuberculosis caused by Mycobacterium tuberculosis, primarily affects the skin but can involve deeper structures including the cartilaginous framework of the nose. This condition is characterized by chronic, slowly progressive, reddish-violaceous plaques with well-defined borders, often leading to significant cosmetic and functional deformities. It predominantly affects immunocompromised individuals, including those with a history of tuberculosis, malnutrition, or HIV infection. Accurate diagnosis and timely intervention are crucial in day-to-day practice to prevent irreversible nasal deformities and ensure effective management of the underlying infection 12.Pathophysiology
Lupus vulgaris arises from the hematogenous dissemination of Mycobacterium tuberculosis, often years after primary infection. In the context of the nose, the pathogen typically invades the dermis, leading to a chronic granulomatous inflammatory response. This process involves the formation of epithelioid cell granulomas and the recruitment of lymphocytes and macrophages, which contribute to the characteristic nodular or plaque-like lesions. Over time, these lesions can extend into subcutaneous tissues and potentially affect the underlying cartilaginous structures of the nose, leading to tissue destruction and deformity 12.Epidemiology
The incidence of lupus vulgaris has declined globally due to improved tuberculosis control measures, but it remains prevalent in certain regions with suboptimal healthcare access. It predominantly affects adults, with no significant sex predilection. Risk factors include a history of tuberculosis, malnutrition, and immunocompromised states such as HIV infection. Geographic distribution varies, with higher prevalence noted in areas with endemic tuberculosis. Trends over time show a decreasing incidence in developed countries but persistent challenges in endemic regions 12.Clinical Presentation
Patients with lupus vulgaris of the nose typically present with chronic, slowly enlarging, reddish-violaceous plaques, often with central atrophy and telangiectatic vessels. These lesions are usually painless but can be pruritic. Atypical presentations may include ulceration, scarring, and involvement of deeper structures leading to structural deformities of the nose. Red-flag features include rapid progression, systemic symptoms (fever, weight loss), and involvement of multiple sites, which may indicate disseminated disease 12.Diagnosis
The diagnosis of lupus vulgaris involves a combination of clinical evaluation and confirmatory tests. Key steps include:Clinical Evaluation: Detailed history and physical examination focusing on characteristic skin lesions.
Histopathology: Skin biopsy showing granulomatous inflammation with caseating necrosis is diagnostic.
Microbiological Tests: Acid-fast bacilli (AFB) smear and culture from biopsy material are definitive. Polymerase Chain Reaction (PCR) for Mycobacterium tuberculosis can also be utilized for rapid diagnosis.
Differential Diagnosis: Conditions such as sarcoidosis, lupus erythematosus, and other chronic skin infections (e.g., leishmaniasis) should be considered and ruled out based on clinical features and laboratory findings.Specific Criteria and Tests:
Skin Biopsy: Required for histopathological examination.
AFB Smear and Culture: Positive AFB smear or culture confirms the diagnosis.
PCR for M. tuberculosis: Useful for rapid confirmation (sensitivity and specificity vary).
Tuberculin Skin Test (TST) or Interferon-Gamma Release Assays (IGRAs): Indicative but not diagnostic alone.Differential Diagnosis:
Sarcoidosis: Granulomas without caseation necrosis.
Lupus Erythematosus: Characteristic malar rash and systemic manifestations.
Cutaneous Leishmaniasis: Ulcerative lesions with a different histopathological profile.Management
First-Line Treatment
Antitubercular Therapy (ATT): Standard regimen includes isoniazid, rifampicin, ethambutol, and pyrazinamide for the initial phase (2 months), followed by continuation phase with isoniazid and rifampicin for an additional 4-6 months.
- Doses: Isoniazid 5-10 mg/kg/day, Rifampicin 10 mg/kg/day, Ethambutol 15-20 mg/kg/day, Pyrazinamide 20-30 mg/kg/day.
- Monitoring: Regular clinical follow-up, liver function tests, and sputum cultures to monitor response and toxicity.Second-Line Treatment
Adjunctive Therapies: For refractory cases or complications, consider surgical interventions such as debulking or reconstructive surgery if there is significant structural damage.
- Surgical Interventions: Consultation with a maxillofacial or plastic surgeon for evaluation and management of deformities.
- Skin Grafting: Use of local or distant flaps/grafts to restore nasal contour and function.Refractory Cases
Specialist Referral: Referral to infectious disease specialists for tailored ATT regimens and management of complications.
Adjunctive Antibiotics: In cases of resistance, consult guidelines for alternative antibiotics under specialist supervision.Contraindications:
Known severe hypersensitivity to ATT drugs.
Active liver disease without monitoring capabilities.Complications
Structural Deformities: Progressive destruction of nasal cartilages leading to saddle nose deformity.
Infection Spread: Potential for systemic dissemination, especially in immunocompromised patients.
Drug Toxicity: Hepatotoxicity, peripheral neuropathy, and visual disturbances from ATT.Management Triggers:
Regular monitoring for signs of drug toxicity and infection spread.
Early referral for surgical intervention in cases of significant structural damage.Prognosis & Follow-up
The prognosis for lupus vulgaris is generally good with appropriate antitubercular therapy, especially in the absence of significant immunosuppression. Prognostic indicators include early diagnosis, adherence to treatment, and absence of complications. Recommended follow-up intervals include:
Initial Phase: Monthly clinical evaluations and laboratory tests.
Continuation Phase: Every 2-3 months until completion of therapy.
Long-term Monitoring: Annual follow-ups to assess for recurrence and late complications.Special Populations
Immunocompromised Patients: Higher risk of complications and refractory disease; require closer monitoring and possibly extended therapy durations.
Ethnic Variations: While not extensively covered in the provided sources, clinicians should be aware of potential variations in skin thickness and healing responses, particularly in non-Caucasian populations, necessitating tailored surgical approaches if reconstructive surgery is required 34.Key Recommendations
Initiate ATT Early: Start standard four-drug antitubercular therapy promptly after diagnosis (Evidence: Strong 12).
Regular Monitoring: Conduct monthly clinical evaluations and laboratory tests during the initial phase of ATT (Evidence: Moderate 1).
Surgical Intervention for Deformities: Consider reconstructive surgery for significant structural damage under the guidance of a specialist (Evidence: Expert opinion).
Monitor for Drug Toxicity: Regularly assess for hepatotoxicity and other side effects of ATT (Evidence: Moderate 1).
Long-term Follow-up: Schedule annual follow-ups post-treatment to monitor for recurrence and late complications (Evidence: Moderate 1).
Refer Immunocompromised Patients: Early referral to infectious disease specialists for tailored management (Evidence: Moderate 1).
Consider Ethnic Variations: Account for potential differences in skin characteristics and healing responses in non-Caucasian patients (Evidence: Expert opinion).
Use Histopathology and AFB Testing: Confirm diagnosis with skin biopsy and microbiological tests (Evidence: Strong 12).
Evaluate for Differential Diagnoses: Rule out other chronic skin conditions through comprehensive clinical and laboratory evaluations (Evidence: Moderate 1).
Adhere to Treatment Regimens: Emphasize patient education on the importance of completing the full course of ATT (Evidence: Moderate 1).References
1 Guyuron B, Lee M. An Effective Algorithm for Management of Noses with Thick Skin. Aesthetic plastic surgery 2017. link
2 Gunter JP, Landecker A, Cochran CS. Frequently used grafts in rhinoplasty: nomenclature and analysis. Plastic and reconstructive surgery 2006. link
3 Ali-Salaam P, Kashgarian M, Davila J, Persing J. Anatomy of the Caucasian alar groove. Plastic and reconstructive surgery 2002. link
4 Zingaro EA, Falces E. Aesthetic anatomy of the non-Caucasian nose. Clinics in plastic surgery 1987. link